Medical Marijuana, Inc. Reports $7.8 Million in Net Revenue in 2022 First Quarter Financial and Operational Results
19. Mai 2022 09:00 ET
|
Medical Marijuana, Inc.
SAN DIEGO, CA, May 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that...
FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good for Consumers and the Economy
05. Juni 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 05, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical Trials on Treatment of Periodontitis
03. Juni 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Selling Company
15. Mai 2019 15:29 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “AXIM”, or the “Company”), a world leader in cannabinoid research and development, today...
AXIM® Biotechnologies to Present at Cannastocks 2019 Q1 Conference
14. Mai 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “Axim”, or the “Company”), a world leader in cannabinoid research and development, today...
AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
09. Mai 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced...
New U.S. Patent Allowance Granted to AXIM® Biotech for Use of All Cannabinoids in Its Controlled-Release Chewing Gum Products
16. November 2016 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Nov. 16, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in hemp cannabinoid research and development, today announced that the United...
AXIM Biotechnologies, Inc. CEO to Speak on Emerging Markets and Cannabis Drug Market at Money Show Dallas
19. Oktober 2016 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that its Chief Executive...
AXIM Biotechnologies, Inc. CEO to Speak at First-Ever National Symposium on Medical Cannabis for Healthcare Professionals in Mexico City
06. Oktober 2016 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Oct. 06, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that its Chief Executive...
AXIM® Biotech Signs Exclusive Distribution Agreement With Israel’s Rafa Pharmaceuticals
19. September 2016 09:00 ET
|
AXIM Biotechnologies, Inc
RAFA to Distribute Axim’s Award-Winning Cannabinoid Chewing Gum CanChew®NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), an innovative biotechnology company...